<DOC>
	<DOC>NCT02014506</DOC>
	<brief_summary>Purpose of study: This phase I/II trial is to evaluate the safety and feasibility of TCRαβ-depleted graft from haploidentical family donors in treating children and adolescents with malignant or non-malignant diseases.</brief_summary>
	<brief_title>Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation in Children and Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<criteria>A. Disease inclusions 1. Hematologic malignancy: Acute lymphoblastic leukemia including induction failure, CR1 (Ph+, t(4:11), hypodiploid and other very high risk features), ≥ CR2, infant ALL with MLL or other unfavorable features Acute myeloid leukemia excluding CR1 with t(8:21), inv(16), t(15:17), and Down syndrome Myelodysplastic syndrome: RCC with 7 or RCC in need of transfusion Chronic myeloid leukemia in AP Juvenile myelomonocytic leukemia Malignant lymphoma, NHL or HD, after failed autologous HSCT Other 2. Nonhematologic malignancy Relapsed or refractory solid tumors including neuroblastoma, rhabdomyosarcoma and so on 3. Nonmalignant hematologic disease Acquired severe and very severe aplastic anemia Fanconi anemia Paroxysmal nocturnal hemoglobinuria Congenital dyserythropoietic anemia Others 4. Inherited or metabolic disease Hemophagocytic lymphohistiocytosis Malignant osteopetrosis Storage diseases Others B. Recipient inclusions 1. Age &lt; 21 years 2. No HLAidentical stem cell donor available 3. LanskyPlay performance score &gt;60 4. No active infection at the time of transplantation 1. HIVinfection 2. Presence of active and serious infection 3. Cardiac ejection fraction &lt;35% on echocardiography 4. Severe pulmonary dysfunction (DLCO &lt;30%) 5. Liver function abnormalities with bilirubin &gt;4mg/dL and elevation of transaminases &gt; 400U/L 6. Concurrent severe or uncontrolled medical disease 7. Patients who are pregnant 8. Patients unwilling or unable to comply with the protocol or unable to give informed consent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Children and adolescents</keyword>
	<keyword>Malignant disease</keyword>
	<keyword>Non-malignant disease</keyword>
	<keyword>TCRαβ depletion</keyword>
	<keyword>Haploidentical hematopoietic stem cell transplantation</keyword>
</DOC>